The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate
Abstract
To compare the clinical usefulness of the serum markers prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), we measured them by radioimmunoassay in 2200 serum samples from 699 patients, 378 of whom had prostatic cancer. PSA was elevated in 122 of 127 patients with newly diagnosed, untreated prostatic cancer, including 7 of 12 patients with unsuspected early disease and all of 115 with more advanced disease. The PSA level increased with advancing clinical stage and was proportional to the estimated volume of the tumor. The PAP concentration was elevated in only 57 of the patients with cancer and correlated less closely with tumor volume. PSA was increased in 86 percent and PAP in 14 percent of the patients with benign prostatic hyperplasia. After radical prostatectomy for cancer, PSA routinely fell to undetectable levels, with a half-life of 2.2 days. If initially elevated, PAP fell to normal levels within 24 hours but always remained detectable. In six patients followed postoperatively by means of repeated measurements, PSA--but not PAP--appeared to be useful in detecting residual and early recurrence of tumor and in monitoring responses to radiation therapy. Prostate massage increased the levels of both PSA and PAP approximately 1.5 to 2 times. Needle biopsy and transurethral resection increased both considerably. We conclude that PSA is more sensitive than PAP in the detection of prostatic cancer and will probably be more useful in monitoring responses and recurrence after therapy. However, since both PSA and PAP may be elevated in benign prostatic hyperplasia, neither marker is specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1977) · CERN Document Server (European Organization for Nuclear Research) · Cited by 1,548
Lilja, H. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112185 · Cited by 734
PATTERNS OF PROGRESSION IN PROSTATE CANCER
Mcneal, J., Kindrachuk, R., Freiha, F., Bostwick, D., Redwine, E., & Stamey, T. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90715-4 · Cited by 582
Self-citationHuman prostate-specific antigen: structural and functional similarity with serine proteases.
Watt, K. W., Lee, P. J., M'Timkulu, T., Chan, W. P., & Loor, R. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.10.3166 · Cited by 560
Postcoital Detection of a Male-Specific Semen Protein: Application to the Investigation of Rape
Graves, H. C. B., Sensabaugh, G. F., & Blake, E. T. (1985) · New England Journal of Medicine · doi:10.1056/nejm198502073120603 · Cited by 191
Serum Prostatic Antigen Measurement in Localized Prostatic Cancer: Correlation with Clinical Course
Pontes, J. E., Chu, T. M., Slack, N. H., Karr, J., & Murphy, G. P. (1982) · The Journal of Urology · doi:10.1016/s0022-5347(17)53431-x · Cited by 64
Henneberry, M. O., Engel, G., & Grayhack, J. T. (1979) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)01218-0 · Cited by 58
Cited by
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., Dekernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., et al. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)35233-3 · Cited by 1,592
Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I., & Walsh, P. C. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)35410-1 · Cited by 1,278
Oesterling, J. E. (1991) · Journal of Urology · doi:10.1016/s0022-5347(17)38491-4 · Cited by 1,230
Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease
Carter, H. B. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480160073037 · Cited by 1,096
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., David Crawford, E., Fogel, R., Gelmann, E. P., Gilbert, F., Hasson, M. A., et al. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00098-2 · Cited by 1,037
Gratzke, C., Bachmann, A., Descazeaud, A., Drake, M. J., Madersbacher, S., Mamoulakis, C., Oelke, M., Tikkinen, K. A. O., & Gravas, S. (2015) · European Urology · doi:10.1016/j.eururo.2014.12.038 · Cited by 1,010
Catalona, W. J. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510080052031 · Cited by 998
American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010
Wolf, A. M. D., Wender, R. C., Etzioni, R. B., Thompson, I. M., D'Amico, A. V., Volk, R. J., Brooks, D. D., Dash, C., Guessous, I., Andrews, K., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20066 · Cited by 965
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
Lilja, H., Ulmert, D., & Vickers, A. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2351 · Cited by 921
Protein Glycosylation in Cancer
Stowell, S. R., Ju, T., & Cummings, R. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040438 · Cited by 873
Stamey, T. A., Kabalin, J. N., Mcneal, J. E., Johnstone, I. M., Freiha, F., Redwine, E. A., & Yang, N. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)41175-x · Cited by 871
Self-citationStamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S., & Schmid, H.-P. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l · Cited by 799
Self-citationCooner, W. H., Mosley, B. R., Rutherford, C. L., Beard, J. H., Pond, H. S., Terry, W. J., Igel, T. C., & Kidd, D. D. (1990) · Journal of Urology · doi:10.1016/s0022-5347(17)40211-4 · Cited by 767
Gittes, R. F. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101243240406 · Cited by 738
Biology of Prostate-Specific Antigen
Balk, S. P., Ko, Y.-J., & Bubley, G. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.083 · Cited by 718
Catalona, W. J. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530150038031 · Cited by 679
The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease*
Yousef, G. M., & Diamandis, E. P. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0424 · Cited by 675
The emerging roles of human tissue kallikreins in cancer
Borgoño, C. A., & Diamandis, E. P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1474 · Cited by 650
Erho, N., Crisan, A., Vergara, I. A., Mitra, A. P., Ghadessi, M., Buerki, C., Bergstralh, E. J., Kollmeyer, T., Fink, S., Haddad, Z., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066855 · Cited by 644
Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate
Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., & Simons, J. W. (1995) · Nature Medicine · doi:10.1038/nm0995-944 · Cited by 622
PROSTATE SPECIFIC ANTIGEN: A DECADE OF DISCOVERY-WHAT WE HAVE LEARNED AND WHERE WE ARE GOING
POLASCIK, T. J., OESTERLING, J. E., & PARTIN, A. W. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68543-6 · Cited by 599
Welch, H. G., & Albertsen, P. C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp278 · Cited by 575
A contemporary approach to validity arguments: a practical guide to Kane's framework
Cook, D. A., Brydges, R., Ginsburg, S., & Hatala, R. (2015) · Medical Education · doi:10.1111/medu.12678 · Cited by 554
STAMEY, T. A., CALDWELL, M., McNEAL, J. E., NOLLEY, R., HEMENEZ, M., & DOWNS, J. (2004) · Journal of Urology · doi:10.1097/01.ju.0000139993.51181.5d · Cited by 545
Self-citationZhao, X.-Y., Malloy, P. J., Krishnan, A. V., Swami, S., Navone, N. M., Peehl, D. M., & Feldman, D. (2000) · Nature Medicine · doi:10.1038/76287 · Cited by 536
Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker
Hernández, J., & Thompson, I. M. (2004) · Cancer · doi:10.1002/cncr.20480 · Cited by 527
Van den Broeck, T., van den Bergh, R. C. N., Arfi, N., Gross, T., Moris, L., Briers, E., Cumberbatch, M., De Santis, M., Tilki, D., Fanti, S., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.10.011 · Cited by 523
Clinical use of Prostate Specific Antigen in Patients with Prostate Cancer
Hudson, M. A., Bahnson, R. R., & Catalona, W. J. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)38972-3 · Cited by 491
Pilepich, M. V., Sause, W. T., Shipley, W. U., Krall, J. M., Lawton, C. A., Grignon, D., Al-Sarraf, M., Abrams, R. A., Caplan, R., John, M. J., et al. (1995) · Urology · doi:10.1016/s0090-4295(99)80053-3 · Cited by 487
Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003180 · Cited by 472
Guise, T. A., & Mundy, G. R. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0323 · Cited by 472
SERUM PSA AFTER ANATOMIC RADICAL PROSTATECTOMY
Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I., & Walsh, P. C. (1993) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)00924-1 · Cited by 460
Kupelian, P. A., Potters, L., Khuntia, D., Ciezki, J. P., Reddy, C. A., Reuther, A. M., Carlson, T. P., & Klein, E. A. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00784-3 · Cited by 457
PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome
Deras, I. L., Aubin, S. M. J., Blase, A., Day, J. R., Koo, S., Partin, A. W., Ellis, W. J., Marks, L. S., Fradet, Y., Rittenhouse, H., et al. (2008) · Journal of Urology · doi:10.1016/j.juro.2007.11.038 · Cited by 453
Fuks, Z., Leibel, S. A., Wallner, K. E., Begg, C. B., Fair, W. R., Anderson, L. L., Hilaris, B. S., & Whitmore, W. F. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90668-t · Cited by 448
Xing, N. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.409 · Cited by 416
Making the most out of six systematic sextant biopsies
Stamey, T. A. (1995) · Urology · doi:10.1016/s0090-4295(95)96168-2 · Cited by 412
Self-citationAge-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men
Morgan, T. O., Jacobsen, S. J., McCarthy, W. F., Jacobson, D. J., McLeod, D. G., & Moul, J. W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608013350502 · Cited by 412
Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer
Malik, A., Afaq, F., Sarfaraz, S., Adhami, V. M., Syed, D. N., & Mukhtar, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505870102 · Cited by 401
Schmid, H.-P., McNeal, J. E., & Stamey, T. A. (1993) · Cancer · doi:10.1002/1097-0142(19930315)71:6<2031::aid-cncr2820710618>3.0.co;2-q · Cited by 401
Self-citationThe Clinical Usefulness of Prostate Specific Antigen: Update 1994
Partin, A. W., & Oesterling, J. E. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)32422-9 · Cited by 390
Targeted proteomic strategy for clinical biomarker discovery
Schiess, R., Wollscheid, B., & Aebersold, R. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2008.12.001 · Cited by 373
Serum Prostate Specific Antigen as Pre-Screening Test for Prostate Cancer
Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.-L., & Emond, J. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37402-5 · Cited by 337
Zhang, H., Yang, L., Zhu, Y., Yao, X., Zhang, S., Dai, B., Zhu, Y., Shen, Y., Shi, G., & Ye, D. (2011) · The Prostate · doi:10.1002/pros.21246 · Cited by 322
Kattan, M. W., Zelefsky, M. J., Kupelian, P. A., Scardino, P. T., Fuks, Z., & Leibel, S. A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3352 · Cited by 320
Rittenhouse, H. G., Finlay, J. A., Mikolajczyk, S. D., & Partin, A. W. (1998) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408369891234219 · Cited by 303
Gupta, S., Afaq, F., & Mukhtar, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205474 · Cited by 295
The emerging role of extracellular vesicles as biomarkers for urogenital cancers
Nawaz, M., Camussi, G., Valadi, H., Nazarenko, I., Ekström, K., Wang, X., Principe, S., Shah, N., Ashraf, N. M., Fatima, F., et al. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.301 · Cited by 294
Prostate-specific antigen: biochemistry, analytical methods, and clinical application
Armbruster, D. A. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.2.181 · Cited by 285
Occult Prostate Cancer in Men With Low Serum Testosterone Levels
Morgentaler, A. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540230054035 · Cited by 279
Exosomes as Biomarker Treasure Chests for Prostate Cancer
Duijvesz, D., Luider, T., Bangma, C. H., & Jenster, G. (2011) · European Urology · doi:10.1016/j.eururo.2010.12.031 · Cited by 278
Proteomic Analysis of Formalin-fixed Prostate Cancer Tissue
Hood, B. L., Darfler, M. M., Guiel, T. G., Furusato, B., Lucas, D. A., Ringeisen, B. R., Sesterhenn, I. A., Conrads, T. P., Veenstra, T. D., & Krizman, D. B. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500102-mcp200 · Cited by 278
Smith, R. A., Cokkinides, V., Brooks, D., Saslow, D., Shah, M., & Brawley, O. W. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20096 · Cited by 275
Lawrence, M. G., Lai, J., & Clements, J. A. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0034 · Cited by 265
Nucleic Acid Tests for Clinical Translation
Li, M., Yin, F., Song, L., Mao, X., Li, F., Fan, C., Zuo, X., & Xia, Q. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00241 · Cited by 264
Novel diagnostic biomarkers for prostate cancer
Madu, C. O., & Lu, Y. (2010) · Journal of Cancer · doi:10.7150/jca.1.150 · Cited by 261
Stability and reproducibility of proteomic profiles measured with an aptamer-based platform
Kim, C. H., Tworoger, S. S., Stampfer, M. J., Dillon, S. T., Gu, X., Sawyer, S. J., Chan, A. T., Libermann, T. A., & Eliassen, A. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-26640-w · Cited by 170
Seaton, A., Scullin, P., Maxwell, P. J., Wilson, C., Pettigrew, J., Gallagher, R., O'Sullivan, J. M., Johnston, P. G., & Waugh, D. J. J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn109 · Cited by 143
Exosomal Secretion of Cytoplasmic Prostate Cancer Xenograft-derived Proteins
Jansen, F. H., Krijgsveld, J., van Rijswijk, A., van den Bemd, G.-J., van den Berg, M. S., van Weerden, W. M., Willemsen, R., Dekker, L. J., Luider, T. M., & Jenster, G. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800443-mcp200 · Cited by 107
Blaszczyk, N., Masri, B. A., Mawji, N. R., Ueda, T., McAlinden, G., Duncan, C. P., Bruchovsky, N., Schweikert, H.-U., Schnabel, D., Jones, E. C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0974-3 · Cited by 66
Drabovich, A. P., Saraon, P., Drabovich, M., Karakosta, T. D., Dimitromanolakis, A., Hyndman, M. E., Jarvi, K., & Diamandis, E. P. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001612 · Cited by 40
Wan, X. S., Ware, J. H., Zhang, L., Newberne, P. M., Evans, S. M., Clark, L. C., & Kennedy, A. R. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19991201)41:4<243::aid-pros4>3.0.co;2-f · Cited by 38
Metadata
- Authors
- Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1987-10-08
- Volume
- 317
- Issue
- 15
- Pages
- 909-916
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2330292521
- Cited by
- 2,451
- References
- 7
- FWCI
- 69.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.